3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Lymphoma
16
Lymphoma, Non-Hodgkin
11
Lymphoma, Large B-Cell, Diffuse
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Leukemia, Lymphocytic, Chronic, B-Cell
7
Hodgkin Disease
7
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Myeloid, Acute
6
Lymphoma, Mantle-Cell
5
Lymphoma, Follicular
5
Small Cell Lung Carcinoma
4
Neuroblastoma
4
Burkitt Lymphoma
4
Testicular Neoplasms
3
Sarcoma
3
Lymphoma, T-Cell
3
Leukemia
3
Central Nervous System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Waldenstrom Macroglobulinemia
2
Testicular Germ Cell Tumor
2
Teratoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Osteosarcoma
2
Neoplasms, Germ Cell and Embryonal
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Interventions
Temozolomide
10
Cyclophosphamide
10
Vincristine
9
Etoposide
6
Doxorubicin
6
Irinotecan
5
palbociclib
4
cabozantinib
4
Topotecan
4
Melphalan
4
Magnetic Resonance Spectroscopy
4
X-Rays
3
Sirolimus
3
Phantoms, Imaging
3
Ifosfamide
3
Gemcitabine
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
ivosidenib
2
irinotecan sucrosofate
2
ganitumab
2
cixutumumab
2
Vemurafenib
2
Trabectedin
2
Tacrolimus
2
Specimen Handling
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sarcoma, Ewing
×
etoposide phosphate
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled